Company: ARWR
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001628280-25-024666
Chunk: 22

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
,063 Total Liabilities, Noncontrolling Interest and Stockholders’ Equity$1,573,498 $1,139,802  

The accompanying notes are an integral part of these unaudited consolidated financial statements. 

1

Arrowhead Pharmaceuticals, Inc.

Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except per share amounts)

(unaudited) 

Three Months Ended March 31,Six Months Ended March 31,2025202420252024Revenue$542,709 $— $545,209 $3,551 Operating expenses:Research and development133,102 101,122 270,104 217,613 General and administrative28,405 25,069 55,315 48,674 Total operating expenses161,507 126,191 325,419 266,287 Operating income (loss)381,202 (126,191)219,790 (262,736)Other income (expense):Interest income9,615 6,250 17,217 9,052 Interest expense(21,639)(7,244)(43,285)(12,611)Other, net438 189 779 610 Total other expense(11,586)(805)(25,289)(2,949)Income (loss) before income tax expense and noncontrolling interest369,616 (126,996)194,501 (265,685)Income tax expense (benefit) 1,753 — 1,856 (3,313)Net income (loss) including noncontrolling interest$367,863 $(126,996)$192,645 $(262,372)Net loss attributable to noncontrolling interest, net of tax(2,582)(1,696)(4,715)(4,208)Net income (loss) attributable to Arrowhead Pharmaceuticals, Inc.$370,445 $(125,300)$197,360 $(258,164)Net income (loss) per share attributable to Arrowhead Pharmaceuticals, Inc.:Basic$2.78 $(1.02)$1.53 $(2.24)Diluted$2.75 $(1.02)$1.52 $(2.24)Weighted-average shares used in calculatingBasic133,363 123,285 129,059 115,307 Diluted134,484 123,285 130,265